Targeting Therapeutics to the Glomerulus With Nanoparticles

Advances in Chronic Kidney Disease

Volumn 20, Issue 6, 2013, Pages 500-507

  Zuckerman, Jonathan E ^a   Davis, Mark E ^a  

^a California Institute of Technology   (United States)

Author keywords

Drug targeting; Glomerulonephritis; Glomerulus; Kidney; Nanoparticles

Indexed keywords

ANTINEOPLASTIC AGENT; CREATININE; DEXAMETHASONE; GOLD NANOPARTICLE; LIPOSOME; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NANOPARTICLE; PREDNISOLONE; SMALL INTERFERING RNA; SYNAPTOPODIN; TRANSFERRIN; UREA;

CIRCULATION TIME; CONFOCAL MICROSCOPY; CREATININE CLEARANCE; GLOMERULONEPHRITIS; GLOMERULOPATHY; GLOMERULUS; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION; HUMAN; HYDRODYNAMICS; IMMUNOGLOBULIN A NEPHROPATHY; MESANGIUM; NEPHRITIS; NONHUMAN; PARTICLE SIZE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; SINGLE DRUG DOSE; TRANSCYTOSIS; UREA NITROGEN BLOOD LEVEL; ZETA POTENTIAL;

DRUG TARGETING; GLOMERULONEPHRITIS; GLOMERULUS; KIDNEY; NANOPARTICLES;

ANIMALS; DRUG DELIVERY SYSTEMS; GLOMERULONEPHRITIS; HUMANS; KIDNEY GLOMERULUS; NANOPARTICLES;

EID: 84886399675     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2013.06.003     Document Type: Review

References (41)

1. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7(9):771-782.
2. Schluep T., Cheng J., Khin K.T., Davis M.E. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharmacol 2006, 57(5):654-662.
3. Davis M.E., Zuckerman J.E., Choi C.H.J., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464(7291):1067-1070.
4. Popielarski S.R., Hu-Lieskovan S., French S.W., Triche T.J., Davis M.E. A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 2. Invitro and invivo uptake results. Bioconjug Chem 2005, 16(5):1071-1080.
5. Choi C.H.J., Zuckerman J.E., Webster P., Davis M.E. Targeting kidney mesangium by nanoparticles of defined size. Proc Natl Acad Sci U S A 2011, 108(16):6656-6661.
6. Perico N., Benigni A., Remuzzi G. Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nat Rev Drug Discov 2008, 7(11):936-953.
7. McGrogan A., Franssen C.F.M., De Vries C.S. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 2011, 26(2):414-430.
8. Ruggenenti P., Cravedi P., Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 2010, 6(6):319-330.
9. Udani S., Lazich I., Bakris G.L. Epidemiology of hypertensive kidney disease. Nat Rev Nephrol 2011, 7(1):11-21.
10. Boor P., Ostendorf T., Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010, 6(11):643-656.
11. Mathieson P.W. The podocyte as a target for therapies-new and old. Nat Rev Nephrol 2011, 8(1):52-56.
12. Betsholtz C., Lindblom P., Bjarnegard M., Enge M., Gerhardt H. Role of platelet-derived growth factor in mesangium development and vasculopathies: lessons from platelet-derived growth factor and platelet-derived growth factor receptor mutations in mice. Curr Opin Nephrol Hypertens 2004, 13(1):45-52.
13. Fornoni A., Sageshima J., Wei C., et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011, 3(85):85ra46.
14. Daldrup-Link H.E., Golovko D., Ruffel B., et al. MRI imaging of tumor-associated macrophages with clinically-applicable iron oxide nanoparticles. Clin Cancer Res 2011, 17(7):5695-5704.
15. Lytton-Jean A.K.R., Langer R., Anderson D.G. Five years of siRNA delivery: spotlight on gold nanoparticles. Small 2011, 7(14):1932-1937.
16. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9(8):615-627.
17. Hashizume H., Baluk P., Morikawa S., et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000, 156(4):1363-1380.
18. Choi H.S., Liu W., Misra P., et al. Renal clearance of quantum dots. Nat Biotechnol 2007, 25(10):1165-1170.
19. Chrastina A., Massey K., Schnitzer J.E. Overcoming invivo barriers to targeted nanodelivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2011, 3(4):421-437.
20. Arvizo R.R., Miranda O.R., Moyano D.F., et al. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One 2011, 6(9):e24374.
21. Akinc A., Querbes W., De S., et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 2010, 18(7):1357-1364.
22. Choi C.H.J., Alabi C.A., Webster P., Davis M.E. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A 2010, 107(3):1235-1240.
23. Asgeirsdóttir S.A., Zwiers P.J., Morselt H.W., et al. Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. Ren Physiol 2008, 294(3):F554-F561.
24. Inoue S., Ding H., Portilla-Arias J., et al. Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity. Cancer Res 2011, 71(4):1454-1464.
25. Sraer J.D., Adida C., Peraldi M.N., Rondeau E., Kanfer A. Species-specific properties of the glomerular mesangium. J Am Soc Nephrol 1993, 3(7):1342-1350.
26. Lahdenkari A.-T., Lounatmaa K., Patrakka J., et al. Podocytes are firmly attached to glomerular basement membrane in kidneys with heavy proteinuria. J Am Soc Nephrol 2004, 15(10):2611-2618.
27. Kanwar Y.S., Farquhar M.G. Presence of heparan sulfate in the glomerular basement membrane. Proc Natl Acad Sci U S A 1979, 76(3):1303-1307.
28. Ogawa S., Ota Z., Shikata K., et al. High-resolution ultrastructural comparison of renal glomerular and tubular basement membranes. Am J Nephrol 1999, 19(6):686-693.
29. Zuckerman J.E., Choi C.H.J., Han H., Davis M.E. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc Natl Acad Sci U S A 2012, 109(8):3137-3142.
30. Bennett K.M., Zhou H., Sumner J.P., et al. MRI of the basement membrane using charged nanoparticles as contrast agents. Magn Reson Med 2008, 60(3):564-574.
31. Naeye B., Deschout H., Caveliers V., et al. Invivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier. Biomaterials 2013, 34(9):2350-2358.
32. Ruggiero A., Villa C.H., Bander E., et al. Paradoxical glomerular filtration of carbon nanotubes. Proc Natl Acad Sci U S A 2010, 107(27):12369-12374.
33. Lacerda L., Herrero M.A., Venner K., Bianco A., Prato M., Kostarelos K. Carbon-nanotube shape and individualization critical for renal excretion. Small 2008, 4(8):1130-1132.
34. Scindia Y., Deshmukh U., Thimmalapura P.-R., Bagavant H. Anti-alpha8integrin immunoliposomes in glomeruli of lupus-susceptible mice: a novel system for delivery of therapeutic agents to the renal glomerulus in systemic lupus erythematosus. Arthritis Rheum 2008, 58(12):3884-3891.
35. Liao J., Hayashi K., Horikoshi S., Ushijima H., Kimura J., Tomino Y. Effect of steroid-liposome on immunohistopathology of IgA nephropathy in ddY mice. Nephron 2001, 89(2):194-200.
36. Morimoto K., Kondo M., Kawahara K., et al. Advances in targeting drug delivery to glomerular mesangial cells by long circulating cationic liposomes for the treatment of glomerulonephritis. Pharm Res 2007, 24(5):946-954.
37. Kamps J.A.A.M., Bakker H.I., Zwiers P.J., et al. Site-specific inhibition ofglomerulonephritis progression by targeted delivery of dexamethasoneto glomerular endothelium. Mol Pharmacol 2007, 72(1):121-131.
38. Suana A.J., Tuffin G., Frey B.M., et al. Single application of low-dose mycophenolate mofetil-OX7-immunoliposomes ameliorates experimental mesangial proliferative glomerulonephritis. Pharmacology 2011, 337(2):411-422.
39. Shimizu H., Hori Y., Kaname S., et al. siRNA-based therapy ameliorates glomerulonephritis. J Am Soc Nephrol 2010, 21(4):622-633.
40. Weiss GJ, Chao J, Neidhart JD, et al. First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs. [E-pub ahead of print Feb 9, 2013].
41. Hrkach J., Von Hoff D., Mukkaram Ali M., et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012, 4(4):128ra39.